The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet. SCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.: EXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health. EXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Diagnostic Performance of Machine Learning Analysis of Finger Photoplethysmography for Detection of Coronary Artery Disease (CAD-RADS ≥2)
Timeframe: Typically within 1 months of enrollment.
Long-Term Incident Major Adverse Renal and Cardiovascular Events (MARCE)
Timeframe: 3-8 years
Immune Activation Biomarkers and Prevalent Atherosclerotic Cardiovascular Disease
Timeframe: Typically within 1 months of enrollment
Lipid Mediator Profiles and Prevalent Atherosclerotic Cardiovascular Disease
Timeframe: Typically within 1 months of enrollment
Correlation Between Oral Microbiota Composition and Prevalent Coronary Artery Disease
Timeframe: Typically within 1 months of enrollment
Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Timeframe: Typically within 1 months of enrollment
Prevalence of Abdominal Aortic Aneurysm
Timeframe: Typically within 1 months of enrolment